Mark Farmery, Chief Development Officer 

Oct. 10 | 3:15pm | Rentschler ATMP Ballroom 

Södertälje, Sweden 


Anocca is a Big Biology company – leveraging a precision biology discovery platform to decode the complexity of the human immune system and encode powerful T cell immunotherapies (TCR-T):

  1. Clinical Validation: During 2024, several KRAS TCR-Ts will enter FIH trials in hard-to-treat solid cancer.
  2. Pipeline: More than 40 preclinical TCR-T assets against hard-to-treat solid tumours
  3. Discovery Capability: Anocca’s cell-based platform pushes the frontiers of T-cell biology to expand the scope and scale of TCR-T – delivering libraries of medicines that can have a significant impact on patients with cancer

 Our cell engineering, molecular and genetic tools, automation, and software technologies analyse the complex interactions between real immune cells to identify biologically relevant disease targets and safe, potent TCR-Ts at an industrial scale (the platform can also be applied to vaccine design and autoimmune research). Anocca is owned by a group of private investors and has raised over $150m. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions